{"url_path":"/sec/hit/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2019505/0001213900-26-056707-index.html","accession_number":"0001213900-26-056707","cik":"0002019505","ticker":"HIT","issuer_name":"Health In Tech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2019505/0001213900-26-056707-index.html","primary_entity_key":"0002019505","primary_entity_name":"Health In Tech, Inc."},"word_count":170,"has_tables":true,"body_markdown":"**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**\n\n** **\n\n**(a)****Recent\nSales of Unregistered Equity Securities**\n\n \n\nOn March 25, 2026, we entered into a securities purchase\nagreement with the accredited investors named in the signature pages thereto for a private investment in public equity financing (the\n“PIPE”), which closed on March 27, 2026, resulting in gross proceeds to us of $7.0 million, before deducting placement agent\nfees and offering expenses. In connection with the closing of the PIPE, and in reliance upon the exemption from registration requirements\nof Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder, we issued an aggregate of 5,600,000\nshares of Class A Common Stock at a purchase price of $1.25 per share. We received net proceeds of $6,381,000 after deducting placement\nagent fees and escrow agent fees of $619,000, and intend to use the net proceeds from the PIPE for sales distribution expansion, technology\ndevelopment, and general corporate purposes.\n\n** **\n\n**(b)****Use\nof Proceeds**\n\n** **\n\nNone.\n\n** **\n\n**(c)****Issuer\nPurchases of Equity Securities**\n\n** **\n\nNone."}